One Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

One Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-239	Closed	-$5K	–	563
2018 Q3	$5K	Sell	239 -101	-30%	-$1.92K	﹤0.01%	415
2018 Q2	$6K	Hold	340	–	–	﹤0.01%	379
2018 Q1	$5K	Sell	340 -54	-14%	-$798	﹤0.01%	381
2017 Q4	$6K	Buy	+394	New	+$5.53K	﹤0.01%	395

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

One Wealth Advisors's HZNP Position: Q4 2018 in Review

One Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 239 shares — an estimated $5K sold.

One Wealth Advisors first reported a position in HZNP in Q4 2017 and held it in 4 quarters. The position peaked at $6K in Q2 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

One Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
One Wealth Advisors sold 239 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $5K.
One Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 4 quarters.
One Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6K in Q2 2018.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on One Wealth Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.